S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)

Mirati Therapeutics (MRTX) Earnings Date, Estimates & Call Transcripts

$58.70
-0.10 (-0.17%)
(As of 01/23/2024)
Skip Charts & View Estimated and Actual Earnings Data

MRTX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

MRTX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Mirati Therapeutics Analyst EPS Estimates

Current Year EPS Consensus Estimate:($11.39) EPS
Next Year EPS Consensus Estimate: ($9.81) EPS

MRTX Earnings Date and Information

Mirati Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 27th, 2024 based off prior year's report dates.

Mirati Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
2/27/2024
Estimated)
------- 
11/6/2023Q3 2023($2.83)($2.49)+$0.34($2.49)$18.80 million$16.40 million
8/8/2023Q2 2023($3.23)($3.04)+$0.19($3.04)$13.17 million$13.70 million    
5/9/2023Q1 2023($3.47)($3.18)+$0.29($3.18)$4.80 million$7.17 million    
2/28/2023Q4 2022($3.74)($3.51)+$0.23($3.51)$2.65 million$0.93 million    
11/8/2022Q3 2022($3.46)($3.09)+$0.37($3.09)$4.72 million$5.43 million
8/3/2022Q2 2022($3.53)($3.18)+$0.35($3.18)$2.20 million$5.36 million
5/4/2022Q1 2022($3.37)($3.40)($0.03)($3.40)$0.18 million$0.71 million    
2/28/2022Q4 2021($3.01)($3.72)($0.71)($3.72)$1.41 million$0.30 million    
11/8/2021Q3 2021($2.87)($1.55)+$1.32($1.55)$1.41 million$71.79 million    
8/5/2021Q2 2021($2.40)($3.23)($0.83)($3.23)--
5/6/2021Q1 2021($2.13)($2.67)($0.54)($2.67)$0.17 million$0.01 million  
2/25/2021Q4 2020($2.23)($2.08)+$0.15($2.08)$1.00 million$1.71 million












Mirati Therapeutics Earnings - Frequently Asked Questions

When is Mirati Therapeutics's earnings date?

Mirati Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 27th, 2024 based off last year's report dates. Learn more on MRTX's earnings history.

How much revenue does Mirati Therapeutics generate each year?

Mirati Therapeutics (NASDAQ:MRTX) has a recorded annual revenue of $12.44 million.

How much profit does Mirati Therapeutics generate each year?

Mirati Therapeutics (NASDAQ:MRTX) has a recorded net income of -$740.87 million. MRTX has generated -$12.22 earnings per share over the last four quarters.

What is Mirati Therapeutics's EPS forecast for next year?

Mirati Therapeutics's earnings are expected to grow from ($11.39) per share to ($9.81) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:MRTX) was last updated on 2/23/2024 by MarketBeat.com Staff